Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas

References

• Fletcher CDM, Bridge JA, Hogendoorn P, Mertens C, eds. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press, Bordeaux, France; 2013. IARC WHO Classification of Tumours; No. 5.
   Google Scholar
• Coley WB II. Contribution to the knowledge of sarcoma. Ann Surg. 1891;14(3):199–13. doi:10.1097/00000658-189112000-00015.
   PubMedGoogle Scholar
• Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D’Angelo S, Attia S, Riedel RF, Priebat DA, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493–1501. doi:10.1016/S1470-2045(17)30624-1.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416–426. doi:10.1016/S1470-2045(18)30006-8.
   PubMed Web of Science ®Google Scholar
• Toulmonde M, Penel N, Adam J, Chevreau C, Blay J-Y, Le Cesne A, Bompas E, Piperno-Neumann S, Cousin S, Grellety T, et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol. 2018;4(1):93–97. doi:10.1001/jamaoncol.2017.1617.
   PubMed Web of Science ®Google Scholar
• Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res. 2018;24(6):1260–1270. doi:10.1158/1078-0432.CCR-17-2267.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today. 1992;13(7):265–270. doi:10.1016/0167-5699(92)90008-U.
   PubMedGoogle Scholar
• Atri C, Guerfali FZ, Laouini D. Role of human macrophage polarization in inflammation during infectious diseases. Int J Mol Sci. 2018;19(6):1801. doi:10.3390/ijms19061801.
   PubMed Web of Science ®Google Scholar
• Mackaness GB. The immunological basis of acquired cellular resistance. J Exp Med. 1964;120:105–120. doi:10.1084/jem.120.1.105.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677–686. doi:10.1016/j.it.2004.09.015.
   PubMed Web of Science ®Google Scholar
• Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–896. doi:10.1038/ni.1937.
   PubMed Web of Science ®Google Scholar
• Tarique AA, Logan J, Thomas E, Holt PG, Sly PD, Fantino E. Phenotypic, functional, and plasticity features of classical and alternatively activated human macrophages. Am J Respir Cell Mol Biol. 2015;53(5):676–688. doi:10.1165/rcmb.2015-0012OC.
   PubMed Web of Science ®Google Scholar
• Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P, et al. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer. 2009;125(2):367–373. doi:10.1002/ijc.24401.
   PubMed Web of Science ®Google Scholar
• Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005;65(8):3437–3446. doi:10.1158/0008-5472.CAN-04-4262.
   PubMed Web of Science ®Google Scholar
• Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196(3):254–265. doi:10.1002/path.1027.
   PubMed Web of Science ®Google Scholar
• Zhang QW, Liu L, Gong CY, Shi H-S, Zeng Y-H, Wang X-Z, Zhao Y-W, Wei Y-Q. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One. 2012;7(12):e50946. doi:10.1371/journal.pone.0050946.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin L-X, Carvajal RD, Dickson MA, Gounder M, Keohan ML, Schwartz GK, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46(3):357–365. doi:10.1016/j.humpath.2014.11.001.
   PubMed Web of Science ®Google Scholar
• Kather JN, Horner C, Weis CA, Aung T, Vokuhl C, Weiss C, Scheer M, Marx A, Simon-Keller K. CD163+ immune cell infiltrates and presence of CD54+ microvessels are prognostic markers for patients with embryonal rhabdomyosarcoma. Sci Rep. 2019;9(1):9211. doi:10.1038/s41598-019-45551-y.
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–795. doi:10.1016/j.immuni.2013.10.003.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171(4):950–965 e928. doi:10.1016/j.cell.2017.10.014.
   PubMed Web of Science ®Google Scholar
• Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, Zhu S, Marinelli RJ, Peterse JL, Poulin N, Nielsen TO, et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res. 2008;14(5):1423–1430. doi:10.1158/1078-0432.CCR-07-1712.
   PubMed Web of Science ®Google Scholar
• Ganjoo KN, Witten D, Patel M, Espinosa I, La T, Tibshirani R, van de Rijn M, Jacobs C, West RB. The prognostic value of tumor-associated macrophages in leiomyosarcoma: a single institution study. Am J Clin Oncol. 2011;34(1):82–86. doi:10.1097/COC.0b013e3181d26d5e.
   PubMed Web of Science ®Google Scholar
• George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter SL, et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity. 2017;46(2):197–204. doi:10.1016/j.immuni.2017.02.001.
   PubMed Web of Science ®Google Scholar
• Reinhold MI, Lindberg FP, Plas D, Reynolds S, Peters MG, Brown EJ. In vivo expression of alternatively spliced forms of integrin-associated protein (CD47). J Cell Sci. 1995;108:3419–3425.
   PubMed Web of Science ®Google Scholar
• Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000;288(5473):2051–2054. doi:10.1126/science.288.5473.2051.
   PubMed Web of Science ®Google Scholar
• Fossati-Jimack L, Azeredo da Silveira S, Moll T, Kina T, Kuypers FA, Oldenborg P-A, Reininger L, Izui S, Azeredo da Silveira S, Moll T, et al. Selective increase of autoimmune epitope expression on aged erythrocytes in mice: implications in anti-erythrocyte autoimmune responses. J Autoimmun. 2002;18(1):17–25. doi:10.1006/jaut.2001.0563.
   PubMed Web of Science ®Google Scholar
• Khandelwal S, van Rooijen N, Saxena RK. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. Transfusion. 2007;47(9):1725–1732. doi:10.1111/j.1537-2995.2007.01348.x.
   PubMed Web of Science ®Google Scholar
• Olsson M, Nilsson A, Oldenborg PA. Dose-dependent inhibitory effect of CD47 in macrophage uptake of IgG-opsonized murine erythrocytes. Biochem Biophys Res Commun. 2007;352(1):193–197. doi:10.1016/j.bbrc.2006.11.002.
   PubMed Web of Science ®Google Scholar
• Ishikawa-Sekigami T, Kaneko Y, Okazawa H, Tomizawa T, Okajo J, Saito Y, Okuzawa C, Sugawara-Yokoo M, Nishiyama U, Ohnishi H, et al. SHPS-1 promotes the survival of circulating erythrocytes through inhibition of phagocytosis by splenic macrophages. Blood. 2006;107(1):341–348. doi:10.1182/blood-2005-05-1896.
   PubMed Web of Science ®Google Scholar
• Yamao T, Noguchi T, Takeuchi O, Nishiyama U, Morita H, Hagiwara T, Akahori H, Kato T, Inagaki K, Okazawa H, et al. Negative regulation of platelet clearance and of the macrophage phagocytic response by the transmembrane glycoprotein SHPS-1. J Biol Chem. 2002;277(42):39833–39839. doi:10.1074/jbc.M203287200.
   PubMed Web of Science ®Google Scholar
• Fujioka Y, Matozaki T, Noguchi T, Iwamatsu A, Yamao T, Takahashi N, Tsuda M, Takada T, Kasuga M. A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion. Mol Cell Biol. 1996;16(12):6887–6899. doi:10.1128/MCB.16.12.6887.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271–285. doi:10.1016/j.cell.2009.05.046.
   PubMed Web of Science ®Google Scholar
• Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J, Chang HY, van de Rijn M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA. 2009;106(33):14016–14021. doi:10.1073/pnas.0906549106.
   PubMed Web of Science ®Google Scholar
• Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699–713. doi:10.1016/j.cell.2010.07.044.
   PubMed Web of Science ®Google Scholar
• Edris B, Weiskopf K, Volkmer AK, Volkmer J-P, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB, Fletcher JA, et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci USA. 2012;109(17):6656–6661. doi:10.1073/pnas.1121629109.
   PubMed Web of Science ®Google Scholar
• Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA. 2012;109(17):6662–6667. doi:10.1073/pnas.1121623109.
   PubMed Web of Science ®Google Scholar
• Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286–299. doi:10.1016/j.cell.2009.05.045.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Chung H, Banan B, Manning PT, Ott KC, Lin S, Capoccia BJ, Subramanian V, Hiebsch RR, Upadhya GA, et al. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett. 2015;360(2):302–309. doi:10.1016/j.canlet.2015.02.036.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One. 2015;10(9):e0137345. doi:10.1371/journal.pone.0137345.
   PubMed Web of Science ®Google Scholar
• Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin’s lymphoma. N Engl J Med. 2018;379(18):1711–1721. doi:10.1056/NEJMoa1807315.
   PubMed Web of Science ®Google Scholar
• Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O’Rourke T, Narayanan S, Papadopoulos K, et al. First-in-human, first-in-class phase i trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. 2019;37(12):946–953. doi:10.1200/JCO.18.02018.
   PubMed Web of Science ®Google Scholar
• Ansell S, Chen RW, Flinn IW, Maris MB, O’Connor OA, Johnson LD, Irwin M, Petrova PS, Uger RA, Sievers EL, et al. A phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in patients with relapsed or refractory hematologic malignancies. Blood. 2016;128(22):1812. doi:10.1182/blood.V128.22.1812.1812.
   Google Scholar
• Manna PP, Frazier WA. CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A. Cancer Res. 2004;64(3):1026–1036. doi:10.1158/0008-5472.CAN-03-1708.
   PubMed Web of Science ®Google Scholar
• Rendtlew Danielsen JM, Knudsen LM, Dahl IM, Lodahl M, Rasmussen T. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma. Br J Haematol. 2007;138(6):756–760. doi:10.1111/j.1365-2141.2007.06729.x.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Lee JC, Lee JJ, Kim S, Lee SG, Park S-W, Sung MW, Heo DS. Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. Tumour Biol. 2008;29(1):28–34. doi:10.1159/000132568.
   PubMedGoogle Scholar
• Xu JF, Pan XH, Zhang SJ, Zhao C, Qiu B-S, Gu H-F, Hong J-F, Cao L, Chen Y, Xia B, et al. CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models. Oncotarget. 2015;6(27):23662–23670. doi:10.18632/oncotarget.4282.
   PubMedGoogle Scholar
• Nielsen TO, Hsu FD, O’Connell JX, Gilks CB, Sorensen PHB, Linn S, West RB, Liu CL, Botstein D, Brown PO, et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol. 2003;163(4):1449–1456. doi:10.1016/S0002-9440(10)63502-X.
   PubMed Web of Science ®Google Scholar
• Ng TL, Gown AM, Barry TS, Cheang MCU, Chan AKW, Turbin DA, Hsu FD, West RB, Nielsen TO. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol. 2005;18(1):68–74. doi:10.1038/modpathol.3800272.
   PubMed Web of Science ®Google Scholar
• Steigen SE, Straume B, Turbin D, Chan AKW, Leung S, Nielsen TO, Lindal S. Clinicopathologic factors and nuclear morphometry as independent prognosticators in KIT-positive gastrointestinal stromal tumors. J Histochem Cytochem. 2008;56(2):139–145. doi:10.1369/jhc.7A7333.2007.
   PubMed Web of Science ®Google Scholar
• Cheng H, Dodge J, Mehl E, Liu S, Poulin N, van de Rijn M, Nielsen TO. Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays. Hum Pathol. 2009;40(9):1244–1251. doi:10.1016/j.humpath.2009.01.011.
   PubMed Web of Science ®Google Scholar
• Pacheco M, Nielsen TO. Histone deacetylase 1 and 2 in mesenchymal tumors. Mod Pathol. 2012;25(2):222–230. doi:10.1038/modpathol.2011.157.
   PubMed Web of Science ®Google Scholar
• Endo M, Su L, Nielsen TO. Activating transcription factor 2 in mesenchymal tumors. Hum Pathol. 2014;45(2):276–284. doi:10.1016/j.humpath.2013.09.003.
   PubMed Web of Science ®Google Scholar
• Endo M, de Graaff MA, Ingram DR, Lim S, Lev DC, Briaire-de Bruijn IH, Somaiah N, Bovée JV, Lazar AJ, Nielsen TO, et al. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol. 2015;28(4):587–595. doi:10.1038/modpathol.2014.155.
   PubMed Web of Science ®Google Scholar
• Banito A, Li X, Laporte AN, Roe J-S, Sanchez-Vega F, Huang C-H, Dancsok AR, Hatzi K, Chen -C-C, Tschaharganeh DF, et al. The SS18-SSX oncoprotein Hijacks KDM2B-PRC1.1 to drive synovial sarcoma. Cancer Cell. 2018;33(3):527–541 e528. doi:10.1016/j.ccell.2018.01.018.
   PubMed Web of Science ®Google Scholar
• Terry J, Saito T, Subramanian S, Ruttan C, Antonescu CR, Goldblum JR, Downs-Kelly E, Corless CL, Rubin BP, van de Rijn M, et al. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol. 2007;31(2):240–246. doi:10.1097/01.pas.0000213330.71745.39.
   PubMed Web of Science ®Google Scholar
• Demicco EG, Harms PW, Patel RM, Smith SC, Ingram D, Torres K, Carskadon SL, Camelo-Piragua S, McHugh JB, Siddiqui J, et al. Extensive survey of STAT6 expression in a large series of mesenchymal tumors. Am J Clin Pathol. 2015;143(5):672–682. doi:10.1309/AJCPN25NJTOUNPNF.
   PubMed Web of Science ®Google Scholar
• Dancsok AR, Setsu N, Gao D, Blay J-Y, Thomas D, Maki RG, Nielsen TO, Demicco EG. Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. Mod Pathol. 2019;32(12):1772–1785. doi:10.1038/s41379-019-0312-y.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–830. e814. doi:10.1016/j.immuni.2018.03.023.
   PubMed Web of Science ®Google Scholar
• Edin S, Wikberg ML, Dahlin AM, Rutegård J, Öberg Å, Oldenborg P-A, Palmqvist R. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One. 2012;7(10):e47045. doi:10.1371/journal.pone.0047045.
   PubMed Web of Science ®Google Scholar
• Herwig MC, Bergstrom C, Wells JR, Holler T, Grossniklaus HE. M2/M1 ratio of tumor associated macrophages and PPAR-gamma expression in uveal melanomas with class 1 and class 2 molecular profiles. Exp Eye Res. 2013;107:52–58. doi:10.1016/j.exer.2012.11.012.
   PubMed Web of Science ®Google Scholar
• Jackute J, Zemaitis M, Pranys D, Sitkauskiene B, Miliauskas S, Vaitkiene S, Sakalauskas R. Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer. BMC Immunol. 2018;19(1):3. doi:10.1186/s12865-018-0241-4.
   PubMedGoogle Scholar
• Yahaya MAF, Lila MAM, Ismail S, Zainol M, Afizan N. Tumour-Associated Macrophages (TAMs) in colon cancer and how to reeducate them. J Immunol Res. 2019;2019:2368249. doi:10.1155/2019/2368249.
   PubMed Web of Science ®Google Scholar
• Zheng X, Turkowski K, Mora J, Brüne B, Seeger W, Weigert A, Savai R. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget. 2017;8(29):48436–48452. doi:10.18632/oncotarget.17061.
   PubMedGoogle Scholar
• Shi L, Bian Z, Liu Y. Dual role of SIRPα in macrophage activation: inhibiting M1 while promoting M2 polarization via selectively activating SHP-1 and SHP-2 signal. J Immunol. 2017;198:67.12.
   Web of Science ®Google Scholar
• Yu XY, Qiu WY, Long F, Yang X-P, Zhang C, Xu L, Chang H-Y, Du P, Hou X-J, Yu Y-Z, et al. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety. Biochimie. 2018;151:54–66. doi:10.1016/j.biochi.2018.05.019.
   PubMed Web of Science ®Google Scholar
• Yanagita T, Murata Y, Tanaka D, Motegi S-I, Arai E, Daniwijaya EW, Hazama D, Washio K, Saito Y, Kotani T, et al. Anti-SIRPalpha antibodies as a potential new tool for cancer immunotherapy. JCI Insight. 2017;2(1):e89140. doi:10.1172/jci.insight.89140.
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Castro S, Coker C, Hinchliffe TE, Arpaia N, Danino T. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat Med. 2019;25(7):1057–1063. doi:10.1038/s41591-019-0498-z.
   PubMed Web of Science ®Google Scholar
• Voduc D, Kenney C, Nielsen TO. Tissue microarrays in clinical oncology. Semin Radiat Oncol. 2008;18(2):89–97. doi:10.1016/j.semradonc.2007.10.006.
   PubMed Web of Science ®Google Scholar
• Cornelissen R, Lievense LA, Maat AP, Hendriks RW, Hoogsteden HC, Bogers AJ, Hegmans JP, Aerts JG. Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma. PLoS One. 2014;9(9):e106742. doi:10.1371/journal.pone.0106742.
   PubMed Web of Science ®Google Scholar
• Barros MH, Hauck F, Dreyer JH, Kempkes B, Niedobitek G. Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One. 2013;8:e80908.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337.
   PubMed Web of Science ®Google Scholar
• Land WG. The role of damage-associated molecular patterns in human diseases: part i - promoting inflammation and immunity. Sultan Qaboos Univ Med J. 2015;15:e9–e21.
   PubMedGoogle Scholar
• Hernandez C, Huebener P, Schwabe RF. Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene. 2016;35(46):5931–5941. doi:10.1038/onc.2016.104.
   PubMed Web of Science ®Google Scholar
• He Y, Zha J, Wang Y, Liu W, Yang X, Yu P. Tissue damage-associated “danger signals” influence T-cell responses that promote the progression of preneoplasia to cancer. Cancer Res. 2013;73(2):629–639. doi:10.1158/0008-5472.CAN-12-2704.
   PubMed Web of Science ®Google Scholar